Drug Trial Radar · NCT05678998
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Dec 6, 2022
Primary completion
Dec 23, 2024
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- Werewolf Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Conditions
- Advanced or Metastatic Solid Tumors
- Non-Hodgkin Lymphoma
Interventions
WTX-330Drug
Investigation Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: 4 weeks
- Incidence of Treatment Emergent Adverse EventsTime frame: 24 months
- Incidence of Changes in Clinical Laboratory AbnormalitiesTime frame: 24 months
- Investigator-assessed Objective Response Rate (ORR) by RECIST 1.1 and Immune ORR by iRECIST (for Solid Tumors) or Response by Lugano Criteria (for Lymphomas)Time frame: 24 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth
Scottsdale, Arizona
Emory Winship Cancer Institute of Emory University
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University
Indianapolis, Indiana
Mass General Hospital
Boston, Massachusetts
Facility Name: Roswell Park Comprehensive Cancer Care
Buffalo, New York
Providence Cancer Institute Franz Clinic
Portland, Oregon
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.